CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights
ras
A collection of 41 issues
Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC
This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google
CRC Research Update — September 01, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 30, 2026
Today's colorectal cancer research highlights
Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC
The DEEPER trial presents final analysis of long-term survival outcomes comparing modified-FOLFOXIRI plus cetuximab versus bevacizumab in patients with RAS and BRAF wild-type metastatic colorectal cancer. (Journal of Clinical Oncology)
This
HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance
Skip to content
The CRC Digest
▸ TREATMENT
HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance
Narrative review outlines practical patient selection and treatment sequencing for HER2-targeted therapies in metastatic colorectal cancer, focusing on RAS wild-type disease with HER2 overexpression or ERBB2 amplification, including dual HER2
CRC Research Update — August 28, 2026
Today's colorectal cancer research highlights
Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRC
The phase II DEEPER trial found no differences in progression-free survival or overall survival in the per-protocol set when comparing modified-FOLFOXIRI plus cetuximab versus
CRC Research Update — August 27, 2026
Today's colorectal cancer research highlights
Kazakhstani pilot study profiles KRAS and BRAF mutations using NGS and ddPCR
Skip to content
The CRC Digest
Kazakhstani pilot study profiles KRAS and BRAF mutations using NGS and ddPCR
Researchers used targeted next-generation sequencing and droplet digital PCR to characterize KRAS and BRAF mutations in metastatic colorectal cancer patients from Kazakhstan, where molecular epidemiological data remain limited. (Frontiers in Medicine)
This